Australian Clinical Labs Ltd ACL
ASX · Australia · Health Services
AUD 2.79+0.03 (+0.91%)
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Underlying EBIT margin beats guidance at 9.4%, with strong cash conversion and a clear FY27 roadmap for operational efficiency and shareholder returns.
Australian shares are expected to open lower, reflecting cautious sentiment from Wall Street as U.S. bond yields reach levels not seen since before the 2007 financial crisis. In this climate of economic uncertainty and rising price pressures, investors may consider exploring penny stocks—an investment area that continues to hold relevance despite its somewhat outdated name. These smaller or newer companies can offer surprising value and potential growth, particularly when they demonstrate...
Over the last 7 days, the Australian market has remained flat, but it has risen by 14% over the past year, with earnings expected to grow by 12% per annum in the coming years. The term 'penny stocks' might feel like a relic of past market eras, but they continue to offer potential value and growth opportunities when backed by strong financials. In this article, we explore several penny stocks that stand out for their financial strength and potential long-term growth.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.